We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+55.06%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.8B
AUM Growth
+$694M
Cap. Flow
+$99M
Cap. Flow %
3.54%
Top 10 Hldgs %
54.31%
Holding
75
New
7
Increased
22
Reduced
25
Closed
5

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$63.5M
2
IMNM icon
Immunome
IMNM
+$32.3M
3
BHVN icon
Biohaven
BHVN
+$28.8M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$27.9M
5
ABT icon
Abbott
ABT
+$26.5M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$30M
2
HUM icon
Humana
HUM
+$29.1M
3
ELV icon
Elevance Health
ELV
+$28.8M
4
FOLD
Amicus Therapeutics
FOLD
+$24M
5
DXCM icon
DexCom
DXCM
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.15%
2 Industrials 3.43%
3 Miscellaneous 2.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
1
DELISTED
Immunogen Inc
IMGN
$487M 17.42%
16,423,922
-1,079,495
-6% -$21.5M
KRYS icon
2
Krystal Biotech
KRYS
$10.4B
$215M 7.69%
1,733,189
-270,178
-13% -$30M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$210M 7.53%
14,828,321
-2,116,300
-12% -$24M
SRRK icon
4
Scholar Rock
SRRK
$7.04B
$120M 4.31%
6,402,505
+1,669,257
+35% +$20.8M
RYZB
5
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$115M 4.13%
1,857,706
– –
AUGX
6
DELISTED
Augmedix, Inc. Common Stock
AUGX
$95.8M 3.43%
16,380,327
+750,000
+5% +$3.95M
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$77.4M 2.77%
4,801,540
+326,156
+7% +$4.16M
SPY icon
8
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$67.7M 2.42%
+142,500
New +$63.5M
RGNX icon
9
Regenxbio
RGNX
$638M
$67.5M 2.41%
3,760,690
+1,186,648
+46% +$20.9M
BHVN icon
10
Biohaven
BHVN
$2.33B
$61.8M 2.21%
1,444,365
+925,441
+178% +$28.8M
ZYME icon
11
Zymeworks
ZYME
$2.02B
$60.2M 2.15%
5,790,230
+129,000
+2% +$1.03M
LIVN icon
12
LivaNova
LIVN
$4.43B
$58.8M 2.1%
1,137,068
+36,576
+3% +$1.77M
ALXO icon
13
ALX Oncology
ALXO
$277M
$54.5M 1.95%
3,659,264
+2,375,975
+185% +$22.5M
CTLT
14
DELISTED
CATALENT, INC.
CTLT
$49.4M 1.77%
1,100,466
+226,500
+26% +$9.16M
FATE icon
15
Fate Therapeutics
FATE
$291M
$49.3M 1.76%
13,169,057
+44,630
+0.3% +$105K
PLRX icon
16
Pliant Therapeutics
PLRX
$68.7M
$48.8M 1.75%
2,696,648
+18,549
+0.7% +$282K
KYMR icon
17
Kymera Therapeutics
KYMR
$9.82B
$46.4M 1.66%
1,823,956
-44,551
-2% -$797K
IMNM icon
18
Immunome
IMNM
$3.13B
$41.5M 1.48%
+3,879,415
New +$32.3M
IMVT icon
19
Immunovant
IMVT
$8.51B
$41.2M 1.47%
977,072
-125,442
-11% -$4.62M
BSX icon
20
Boston Scientific
BSX
$67.9B
$40.1M 1.43%
693,200
-81,000
-10% -$4.32M
STTK icon
21
Shattuck Labs
STTK
$707M
$40.1M 1.43%
5,619,914
– –
CLDX icon
22
Celldex Therapeutics
CLDX
$3.07B
$39.4M 1.41%
993,803
-642,135
-39% -$18.9M
BEAM icon
23
Beam Therapeutics
BEAM
$3.03B
$38.9M 1.39%
1,429,783
-39,942
-3% -$992K
ABSI icon
24
Absci
ABSI
$1.49B
$33.7M 1.21%
8,031,094
– –
NRIX icon
25
Nurix Therapeutics
NRIX
$2.72B
$33.6M 1.2%
3,256,519
+407,692
+14% +$2.79M
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2023 Portfolio in Review

As of Q4 2023, Redmile Group held 75 positions worth $2.8B, up 33% from $2.1B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Redmile Group deployed $99M of net new capital in Q4 2023, opening 7 new positions and adding to 22 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 142,500 shares worth $67.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Krystal Biotech, an estimated $30M trimmed.

  • Redmile Group's largest Q4 2023 buy was State Street SPDR S&P 500 ETF Trust: 142,500 shares worth $67.7M.
  • Redmile Group added most to Biohaven in Q4 2023, an estimated $28.8M increase.
  • Redmile Group's biggest Q4 2023 reduction was Krystal Biotech, cutting an estimated $30M.
  • Redmile Group fully exited Humana in Q4 2023, selling an estimated $29.1M.
  • Redmile Group's ten largest holdings make up 54% of its $2.8B portfolio in Q4 2023.
  • Redmile Group opened 7 new positions and closed 5 in Q4 2023.
  • Redmile Group's portfolio value rose 33% quarter-over-quarter to $2.8B.

Based on Redmile Group's 13F filing for Q4 2023, filed 14 Feb 2024.